ASCOPHARM RESSOURCES : revenue, balance sheet and financial ratios

ASCOPHARM RESSOURCES is a French company founded 29 years ago, specialized in the sector Activités spécialisées, scientifiques et techniques diverses. Based in PARIS (75016), this company of category PME shows in 2023 a revenue of 369€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - ASCOPHARM RESSOURCES (SIREN 410739668)
Indicator 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue N/C 369 € N/C N/C N/C N/C 160 069 € 466 120 € 945 409 €
Net income -25 628 € -217 € -24 743 € -5 364 € -887 € -31 289 € 36 578 € 5 421 € -519 €
EBITDA -25 628 € -217 € -27 699 € -5 365 € -887 € -31 289 € 44 405 € -9 200 € -3 826 €
Net margin N/C -58.8% N/C N/C N/C N/C 22.9% 1.2% -0.1%

Revenue and income statement

In 2024, ASCOPHARM RESSOURCES records a net loss of 26 k€. This deficit will reduce equity on the balance sheet.

EBITDA (2024) ?
Gross Operating Surplus (EBITDA)
Definition
Resources generated by current operations, before depreciation and financial expenses.
Formula
Value added - Personnel expenses - Taxes
Interpretation
Positive = profitable activity

-25 628 €

EBIT (2024) ?
EBIT (Operating Income)
Definition
Operating income, including depreciation and provisions.
Formula
EBITDA - Depreciation and provisions + Reversals

-25 628 €

Net income (2024) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

-25 628 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 69%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2024) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

0.233%

Financial autonomy (2024) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

69.068%

Repayment capacity (2024) ?
Repayment capacity
Definition
Number of years needed to repay debts with cash flow.
Formula
Financial debt / Cash flow
Interpretation
< 3 years : Excellent
3-5 years : Fair
> 5 years : Warning

-0.013

Solvency indicators evolution
ASCOPHARM RESSOURCES

Sector positioning

Debt ratio
0.23 2024
2022
2023
2024
Q1: 0.0
Med: 4.67
Q3: 40.89
Good

In 2024, the debt ratio of ASCOPHARM RESSOURCES (0.23) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
69.07% 2024
2022
2023
2024
Q1: 4.58%
Med: 32.74%
Q3: 63.16%
Excellent +9 pts over 3 years

In 2024, the financial autonomy of ASCOPHARM RESSOURCES (69.1%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.

Repayment capacity
-0.01 years 2024
2022
2023
2024
Q1: 0.0 years
Med: 0.0 years
Q3: 0.43 years
Excellent

In 2024, the repayment capacity of ASCOPHARM RESSOURCES (-0.01) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 324.97. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2024) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

324.974

Interest coverage (2024) ?
Interest coverage
Definition
Ability to cover interest charges with operating income.
Formula
EBIT / Interest expenses
Interpretation
> 3 : Comfortable
1.5-3 : Acceptable
< 1.5 : Risk

0.0

Liquidity indicators evolution
ASCOPHARM RESSOURCES

Sector positioning

Liquidity ratio
324.97 2024
2022
2023
2024
Q1: 144.63
Med: 259.05
Q3: 521.3
Good +12 pts over 3 years

In 2024, the liquidity ratio of ASCOPHARM RESSOURCES (324.97) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Interest coverage
0.0x 2024
2022
2023
2024
Q1: 0.0x
Med: 0.0x
Q3: 0.45x
Average

In 2024, the interest coverage of ASCOPHARM RESSOURCES (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 733 days. Excellent situation: suppliers finance 733 days of the operating cycle (retail model).

Operating WCR (2024) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2024) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2024) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

733 j

Inventory turnover (2024) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
ASCOPHARM RESSOURCES

Positioning of ASCOPHARM RESSOURCES in its sector

Comparison with sector Activités spécialisées, scientifiques et techniques diverses

Similar companies (Activités spécialisées, scientifiques et techniques diverses)

Compare ASCOPHARM RESSOURCES with other companies in the same sector:

Voir toutes les statistiques du secteur Activités spécialisées, scientifiques et techniques diverses

Frequently asked questions about ASCOPHARM RESSOURCES

What is the revenue of ASCOPHARM RESSOURCES ?

The revenue of ASCOPHARM RESSOURCES in 2023 is 369€.

Is ASCOPHARM RESSOURCES profitable?

ASCOPHARM RESSOURCES recorded a net loss in 2024.

Where is the headquarters of ASCOPHARM RESSOURCES ?

The headquarters of ASCOPHARM RESSOURCES is located in PARIS (75016), in the department Paris.

Where to find the tax return of ASCOPHARM RESSOURCES ?

The tax return of ASCOPHARM RESSOURCES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does ASCOPHARM RESSOURCES operate?

ASCOPHARM RESSOURCES operates in the sector Activités spécialisées, scientifiques et techniques diverses (NAF code 74.90B). See the 'Sector positioning' section above to compare the company with its competitors.